Irenic Capital Management LP Increases Holdings in Sotera Health (NASDAQ:SHC)

Irenic Capital Management LP grew its position in Sotera Health (NASDAQ:SHC) by 4.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,909,163 shares of the company’s stock after acquiring an additional 120,832 shares during the period. Sotera Health accounts for approximately 4.3% of Irenic Capital Management LP’s investment portfolio, making the stock its 6th biggest position. Irenic Capital Management LP owned 1.03% of Sotera Health worth $39,797,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Xponance Inc. raised its stake in Sotera Health by 6.0% during the fourth quarter. Xponance Inc. now owns 17,495 shares of the company’s stock worth $239,000 after buying an additional 989 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Sotera Health by 2.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company’s stock worth $711,000 after purchasing an additional 1,047 shares in the last quarter. GAMMA Investing LLC raised its position in Sotera Health by 37.5% in the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock valued at $56,000 after buying an additional 1,121 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after purchasing an additional 1,140 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Sotera Health by 37.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company’s stock valued at $82,000 after buying an additional 1,640 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

Sotera Health Stock Performance

Shares of NASDAQ SHC opened at $13.13 on Friday. Sotera Health has a 1-year low of $9.53 and a 1-year high of $17.08. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The stock’s 50-day moving average is $11.45 and its 200 day moving average is $12.93. The stock has a market cap of $3.73 billion, a price-to-earnings ratio of 52.52 and a beta of 1.88.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Thursday, May 1st. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The firm had revenue of $254.52 million for the quarter, compared to the consensus estimate of $245.56 million. During the same quarter in the previous year, the business earned $0.13 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis. On average, sell-side analysts anticipate that Sotera Health will post 0.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SHC shares. Barclays lowered their target price on Sotera Health from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group upgraded Sotera Health from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Finally, Piper Sandler reduced their price target on shares of Sotera Health from $15.00 to $13.00 and set a “neutral” rating for the company in a research report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Sotera Health presently has an average rating of “Moderate Buy” and a consensus price target of $15.80.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.